

## Contents

**Preface** *XIX*

**Preface to First Edition** *XXI*

**List of Abbreviations** *XXIII*

### **Part I: Introduction** *1*

<b>1</b>	<b>Biopharmaceutical Production: Value Creation, Product Types, and Biological Basics Introduction</b>	<b>3</b>
1.1	Role of Production in Pharmaceutical Biotechnology	3
1.1.1	Relationship Between Production and Development	6
1.1.2	Relationship Between Production and Marketing	8
1.2	Product Groups	10
1.2.1	Vaccines	11
1.2.2	Pharmaceuticals from Blood and Organs	11
1.2.3	Recombinant Therapeutic Proteins	13
1.2.4	Cell and Gene Therapeutics	13
1.2.5	Antibiotics	16
1.3	Basics of Biology	16
1.3.1	Cells and Microorganisms	17
1.3.1.1	Structure and Types of Cells	17
1.3.1.2	Metabolism	20
1.3.1.3	Reproduction and Aging	21
1.3.1.4	Viruses and Bacteriophages	22
1.3.1.5	Protein Biosynthesis	24
1.3.2	The Four Molecular Building Blocks of Biochemistry	25
1.3.2.1	Proteins	25
1.3.2.2	Nucleic Acids	30
1.3.2.3	Polysaccharides	30
1.3.2.4	Lipids	31

## Part II: Technology 33

<b>2</b>	<b>Manufacturing Process 35</b>
2.1	Role of the Manufacturing Process in Biotechnology 35
2.2	Process Schematic and Evaluation 37
2.2.1	Drug Substance Manufacturing 38
2.2.2	Drug Product Manufacturing 40
2.2.3	Key Factors for Process Evaluation 41
2.3	Cell Bank 43
2.3.1	Expression Systems 43
2.3.2	Microbial Systems 44
2.3.2.1	Mammalian Systems 45
2.3.2.2	Transgenic Systems 46
2.3.3	Manufacturing and Storage of the Cell Bank 46
2.4	Fermentation 48
2.4.1	Basic Principles 48
2.4.1.1	Cell Growth and Product Expression 49
2.4.1.2	Comparison of Batch and Continuous Processes 50
2.4.1.3	Sterility and Sterile Technology 53
2.4.1.4	Comparison of Fermentation with Mammalian Cells and Microorganisms 55
2.4.2	Technologies and Equipment 56
2.4.2.1	Fermentation in Suspension Culture 56
2.4.2.2	Adherent Cell Cultures 57
2.4.2.3	Transgenic Systems 60
2.4.3	Raw Materials and Processing Aids 61
2.4.3.1	Nutrient Media 61
2.4.3.2	Water, Gases, and Other Processing Aids 62
2.4.4	Overview of Fermentation 63
2.5	Purification 64
2.5.1	Basic Principles 65
2.5.1.1	Basic Pattern of Purification 65
2.5.1.2	Types of Impurities 68
2.5.1.3	Principles of Separation Technologies 71
2.5.2	Technologies for Cell Separation and Product Isolation 73
2.5.2.1	Cell Separation 73
2.5.2.2	Cell Disruption, Solubilization, and Refolding 74
2.5.2.3	Concentration and Stabilization 75
2.5.3	Technologies for Final Purification 80
2.5.3.1	Chromatographic Processes 81
2.5.3.2	Precipitation and Extraction 89
2.5.3.3	Sterile Filtration and Virus Removal 90
2.5.4	Raw Materials and Processing Aids 91

2.5.4.1	Gels for Chromatography	91
2.5.4.2	Membranes for TFF	93
2.5.5	Overview of Purification	94
2.6	Formulation and Filling	96
2.6.1	Basic Principles	96
2.6.2	Freeze-Drying	98
2.7	Labeling and Packaging	99
<b>3</b>	<b>Analytics</b>	<b>103</b>
3.1	Role of Analytics in Biotechnology	103
3.2	Product Analytics	105
3.2.1	Identity	107
3.2.2	Content	107
3.2.3	Purity	109
3.2.4	Activity	109
3.2.5	Appearance	112
3.2.6	Stability	112
3.2.7	Quality Criteria of Analytical Methods	114
3.2.8	Analytical Methods	115
3.2.8.1	Amino Acid Analysis	115
3.2.8.2	Protein Sequencing	116
3.2.8.3	Peptide Mapping	116
3.2.8.4	Protein Content	117
3.2.8.5	Electrophoresis	118
3.2.8.6	Western Blot	120
3.2.8.7	HCP Enzyme-Linked Immunosorbent Assay (ELISA)	122
3.2.8.8	Analytical Chromatography	123
3.2.8.9	Infrared (IR) Spectroscopy	125
3.2.8.10	UV/Vis Spectroscopy	125
3.2.8.11	Mass Spectrometry	125
3.2.8.12	Glycoanalytics	127
3.2.8.13	PCR	127
3.2.8.14	DNA/RNA Sequencing	128
3.2.8.15	Endotoxins and Pyrogen Testing	129
3.2.8.16	Bioburden Test	129
3.2.8.17	Virus Testing	130
3.2.8.18	TEM	130
3.2.8.19	Circular Dichroism	130
3.2.8.20	Differential Scanning Calorimetry	131
3.3	Process Analytics	132
3.3.1	Fermentation	132
3.3.2	Purification	133
3.3.3	Formulation and Packaging	134
3.4	Environmental Monitoring	135

- 3.5 Raw Material Testing 137
- 3.6 Product Comparability 137

### **Part III: Pharmacy 141**

- 4 Pharmacology and Drug Safety 143**
  - 4.1 Action of Drugs in Humans 144
    - 4.1.1 Pharmacokinetics 145
    - 4.1.2 Pharmacodynamics 149
      - 4.1.2.1 Principles of Phenomenological Effects 149
      - 4.1.2.2 Parameters of Drug Effects 150
  - 4.2 Routes and Forms of Administration 152
  - 4.3 Drug Study 153
    - 4.3.1 Pre-Clinical Study 155
    - 4.3.2 Clinical Study 157
      - 4.3.2.1 Phases of Clinical Studies 157
      - 4.3.2.2 Design and Conduct of Clinical Trials 160
  - 4.4 Path of the Drug from the Manufacturer to Patients 162
  - 4.5 Drug Safety 164
    - 4.5.1 Causes and Classification of Side-Effects 165
    - 4.5.2 Methods for Supervising Drug Safety (Pharmacovigilance) 167
    - 4.5.3 Measures upon Incidence of Adverse Reactions 168

### **Part IV: Quality Assurance 171**

- 5 Fundamentals of Quality Assurance 173**
  - 5.1 Basic Principles 173
  - 5.2 Benefit of Quality Assurance Activities 174
  - 5.3 Quality Management According to ISO 9000 176
    - 5.3.1 Fields of Activity 176
  - 5.4 Structure of Quality Management Systems 178
  - 5.5 Quality Management System Components in the Pharmaceutical Area 180
    - 5.5.1 Documentation 180
    - 5.5.2 Failure Prevention and Correction 181
    - 5.5.3 Responsibility of Management and Training of Personnel 185
    - 5.5.4 Audits 186
    - 5.5.5 External Suppliers 187
    - 5.5.6 Contract Review 188
  - 5.6 Quality Assurance in Development 189

<b>6</b>	<b>Quality Assurance in Manufacturing</b>	<b>191</b>
6.1	GMP	191
6.1.1	Personnel	196
6.1.2	Premises and Equipment	198
6.1.2.1	Measures to Avoid External Contamination	198
6.1.2.2	Measures to Avoid Cross-Contamination and Product Confusion	201
6.1.3	Equipment Qualification	203
6.1.4	Process Validation	206
6.1.5	Computer Validation	208
6.1.6	Documentation	209
6.2	Operative Workflows under GMP Conditions	210
6.2.1	Product Release and Deviation Management	211
6.2.2	Changes in the Manufacturing Process	213
6.3	Production of Investigational Drugs	216

## **Appendix A Case Study Part 4: Warning Letters by FDA 219**

### **Part V: Pharmaceutical Law 223**

<b>7</b>	<b>Pharmaceutical Law and Regulatory Authorities</b>	<b>225</b>
7.1	Fields of Pharmaceutical Law	225
7.2	Bindingness of Regulations	226
7.3	Authorities, Institutions, and Their Regulations	228
7.3.1	FDA	228
7.3.2	EMA	231
7.3.3	German Authorities	233
7.3.4	Japanese Authorities	235
7.3.5	Authorities of Growth Markets	236
7.3.5.1	China Food and Drug Administration (CFDA)	236
7.3.5.2	Brazilian Agência Nacional de Vigilância Sanitária (National Health Surveillance Agency, ANVISA)	237
7.3.6	Other Important Institutions	237
7.3.6.1	US Pharmacopoeia	237
7.3.6.2	ICH	237
7.3.6.3	ISO	238
7.3.6.4	WHO	238
7.3.6.5	PIC/S	238
7.3.6.6	ISPE	238
7.3.6.7	PDA	240
7.4	Official Enforcement of Regulations	240
7.5	Drug Approval	242

**Appendix B Case Study Part 5: Clinical Trials for Protein****Products 245**

- B.1 Mabthera®/Rituxan® 245
- B.2 Enbrel® 246
- B.3 Remicade®/Infliximab 247
- B.4 Humira®40 mg 248
- B.5 Lucentis® 249
- B.6 Zaltrap® 249

**Part VI: Production Facilities 251****8 Facility Design 253**

- 8.1 Basic Principles 253
- 8.2 GMP-Compliant Plant Design 256
  - 8.2.1 Production Flow Diagram 258
  - 8.2.2 Conceptual Plant Layout 259
  - 8.2.3 GMP Flow Analysis 263
  - 8.2.4 Zoning Concept 266
- 8.3 Basic Concepts for Production Plants 270
  - 8.3.1 Single- and Multiproduct Plants 271
  - 8.3.2 Fractal and Integrated Configuration 274
  - 8.3.3 Flexible and Fixed Piping 275
  - 8.3.4 Steel Tanks and Disposable Equipment 277
- 8.4 Clean and Plant Utilities 278
  - 8.4.1 Clean Utilities 278
    - 8.4.1.1 Water 278
    - 8.4.1.2 Clean Steam 285
    - 8.4.1.3 Gases and Process Air 285
  - 8.4.2 Plant Utilities 285
  - 8.4.3 Waste Management 288
- 8.5 Equipment Cleaning 289
- 8.6 Clean-Rooms 290
  - 8.6.1 Separation of Zones by Clean-Room Design 291
  - 8.6.2 Finishing of Floors, Walls, and Ceilings 293
  - 8.6.3 HVAC Installations 294
  - 8.6.4 Qualification 295
- 8.7 Automation 296
- 8.8 QC Laboratories 297
- 8.9 Location Factors 298
  - 8.9.1 Cost 298
  - 8.9.2 Personnel 299
  - 8.9.3 Permitting 299
  - 8.9.4 Synergies with Existing Facilities or Units 299
  - 8.9.5 Logistics 299
  - 8.9.6 Know-How and Intellectual Property Protection 300

8.9.7	Other Risks	300
8.9.8	Market Access	300
8.9.9	Language and Culture	300
<b>9</b>	<b>Planning, Construction, and Commissioning of a Manufacturing Plant</b>	<b>301</b>
9.1	Steps of the Engineering Project	301
9.1.1	Planning	302
9.1.2	Construction	303
9.1.3	Commissioning, Qualification, Validation	305
9.2	Project Schedules	308
9.3	Cost Estimates	309
9.4	Organization of an Engineering Project	311
9.4.1	Expert Groups Involved	311
9.4.2	Role and Selection of Contractors	311
9.4.3	Contracts and Scope Changes	312
9.5	Successful Execution of an Engineering Project	316
9.6	Legal Aspects of Facility Engineering	317
9.6.1	Health, Safety, and Environmental Law	318
9.6.2	Building Law	319
	<b>Part VII: Economy</b>	<b>321</b>
<b>10</b>	<b>Production Costs</b>	<b>323</b>
10.1	Drug Life Cycle	323
10.2	Position of the Manufacturing Costs in the Overall Cost Framework	327
10.3	Basic Principles of Cost Calculation	329
10.3.1	Nominal Accounting – Actual Accounting	330
10.3.2	Cost Accounting – Profit and Loss Accounting	330
10.3.3	Direct Costs – Indirect Costs	330
10.3.4	Fixed Costs – Variable Costs	331
10.3.5	Relevant and Irrelevant Costs	333
10.3.6	Cost Type, Cost Center, and Cost Unit	333
10.4	Costs of Biotechnological Manufacturing Processes	334
10.4.1	Capital Costs	335
10.4.2	Operating Costs	337
10.5	Accounting Methods	338
10.5.1	Cost Accounting	347
10.5.2	Profit and Loss Accounting	350
<b>11</b>	<b>Investments</b>	<b>353</b>
11.1	Basic Principles	354
11.1.1	Investment Targets	354

11.1.2	Types of Investments	355
11.1.3	Decision Processes	357
11.2	Value–Benefit Analysis	361
11.3	Investment Appraisal	362
11.3.1	Static Methods	366
11.3.1.1	Cost Comparison	366
11.3.1.2	Profit Comparison	367
11.3.1.3	Profitability Comparison	367
11.3.1.4	Static Payback Time	367
11.3.2	Dynamic Methods	367
11.3.2.1	Capital Value	368
11.3.2.2	Internal Rate of Return	368
11.3.2.3	Annuity	369
11.4	Dynamic Payback Time	369
<b>12</b>	<b>Production Concept</b>	<b>371</b>
12.1	Capacity Planning	371
12.2	Dilemma of In-House Manufacturing	374
12.3	Aspects of Manufacturing Outsourcing	377
12.3.1	Types of Cooperation	378
12.3.2	Contractual Agreements	379
12.3.3	Technology Transfer	384
12.3.4	Time Schedules	386
12.4	Make-or-Buy Analysis	387
12.5	Process Optimization after Market Launch	389
12.6	Supply-Chain Management	391
12.6.1	Security of Supply	393
12.6.2	Performance Management	396
<b>Appendix C Examples Part 7: Manufacturing Cost Calculation 399</b>		
C.1	Introduction	399
C.2	Basic Assumptions for Both Production Processes	399
C.3	Step 1: Production of Product 1 in Dedicated Facility	399
C.3.1	Cost Structure	400
C.3.2	Product Costs	401
C.3.3	Idle Costs	401
C.3.4	Unit Price Based on Facility Usage	401
C.4	Step 2: Addition of a Second Product	402
C.4.1	Costs of Products	403
C.4.2	Evaluation of Manufacturing Options	404



<b>References</b>	<b>407</b>
Further Reading	407
Biotechnology General	407
Fermentation	408
Purification	408
Aseptic Filling and Lyophilization	408
Bioanalytics	408
Regulatory	408
Pharmacy and Clinical Development	409
Quality and Validation	409
Good Manufacturing Practice	410
Facility Design	410
Clean Rooms	410
Project Management	410
Engineering	410
Economy	411
Weblinks	411
 <b>Index</b>	 <b>413</b>